{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T15:05:45Z","timestamp":1776870345322,"version":"3.51.2"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Stanford Clinical and Translational Science Award","award":["UL1 TR001085"],"award-info":[{"award-number":["UL1 TR001085"]}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Contemporary Clinical Trials"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.cct.2017.10.007","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T15:47:35Z","timestamp":1507996055000},"page":"173-178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa"],"prefix":"10.1016","volume":"64","author":[{"given":"Shebani Sethi","family":"Dalai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Adler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Najarian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra Lynn","family":"Safer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.cct.2017.10.007_bb0005","doi-asserted-by":"crossref","first-page":"S51","DOI":"10.1038\/sj.ijo.0801699","article-title":"Binge eating disorder and obesity","volume":"25","author":"de Zwaan","year":"2001","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.cct.2017.10.007_bb0010","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.biopsych.2012.11.020","article-title":"The prevalence and correlates of binge eating disorder in the World Health Organization World Mental Health Surveys","volume":"73","author":"Kessler","year":"2013","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0015","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s40337-015-0056-0","article-title":"Prevalence and sociodemographic correlates of DSM-5 eating disorders in the Australian population","volume":"3","author":"Hay","year":"2015","journal-title":"J. Eat. Disord."},{"key":"10.1016\/j.cct.2017.10.007_bb0020","series-title":"Obesity: Evaluation and Treatment Essentials","article-title":"Binge eating disorder: etiology, assessment, diagnosis and treatment","author":"Carson","year":"2016"},{"key":"10.1016\/j.cct.2017.10.007_bb0025","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s40519-016-0264-x","article-title":"A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder","volume":"21","author":"\u00c1gh","year":"2016","journal-title":"Eat. Weight Disord."},{"key":"10.1016\/j.cct.2017.10.007_bb0030","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.biopsych.2006.03.040","article-title":"The prevalence and correlates of eating disorders in the National Comorbidity Survey Replication","volume":"61","author":"Hudson","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0035","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-5\u00ae)","author":"American Psychiatric Association","year":"2013"},{"key":"10.1016\/j.cct.2017.10.007_bb0040","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.biopsych.2004.11.002","article-title":"Efficacy of cognitive behavioral therapy and fluoxetine for the treatment of binge eating disorder: a randomized double-blind placebo-controlled comparison","volume":"57","author":"Grilo","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0045","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1037\/a0030061","article-title":"12-month follow-up of fluoxetine and cognitive behavioral therapy for binge eating disorder","volume":"80","author":"Grilo","year":"2012","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.cct.2017.10.007_bb0050","doi-asserted-by":"crossref","first-page":"409","DOI":"10.7326\/M15-2455","article-title":"Binge-eating disorder in adults: a systematic review and meta-analysis","volume":"165","author":"Brownley","year":"2016","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.cct.2017.10.007_bb0055","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1001\/archpsyc.59.8.713","article-title":"A randomized comparison of group cognitive-behavioral therapy and group interpersonal psychotherapy for the treatment of overweight individuals with binge-eating disorder","volume":"59","author":"Wilfley","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0060","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.beth.2009.01.006","article-title":"Outcome from a randomized controlled trial of group therapy for binge eating disorder: comparing dialectical behavior therapy adapted for binge eating to an active comparison group therapy","volume":"41","author":"Safer","year":"2010","journal-title":"Behav. Ther."},{"key":"10.1016\/j.cct.2017.10.007_bb0065","series-title":"Mindfulness and acceptance-based interventions: conceptualization, application, and empirical support","article-title":"Mindfulness-based approaches to eating disorders","author":"Kristeller","year":"2006"},{"key":"10.1016\/j.cct.2017.10.007_bb0070","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1037\/0022-006X.68.4.564","article-title":"Stepped care treatment for eating disorders","volume":"68","author":"Wilson","year":"2000","journal-title":"J. Consult. Clin. Psychol."},{"key":"10.1016\/j.cct.2017.10.007_bb0075","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.4088\/JCP.v63n1113","article-title":"A placebo-controlled, randomized trial of fluoxetine in the treatment of binge-eating disorder","volume":"63","author":"Arnold","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0080","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1176\/ajp.155.12.1756","article-title":"Fluvoxamine in the treatment of binge-eating disorder: a multicenter placebo-controlled, double-blind trial","volume":"155","author":"Hudson","year":"1998","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0085","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1176\/appi.ajp.157.6.1004","article-title":"Placebo-controlled trial of sertraline in the treatment of binge eating disorder","volume":"157","author":"McElroy","year":"2000","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0090","doi-asserted-by":"crossref","first-page":"807","DOI":"10.4088\/JCP.v64n0711","article-title":"Citalopram in the treatment of binge-eating disorder: a placebo-controlled trial","volume":"64","author":"McElroy","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0095","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1002\/eat.20946","article-title":"Duloxetine in the treatment of binge eating disorder with depressive disorders: a placebo-controlled trial","volume":"45","author":"Guerdjikova","year":"2012","journal-title":"Int. J. Eat. Disord."},{"key":"10.1016\/j.cct.2017.10.007_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/hup.899","article-title":"High-dose escitalopram in the treatment of binge-eating disorder with obesity: a placebo-controlled monotherapy trial","volume":"23","author":"Guerdjikova","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.10.007_bb0105","doi-asserted-by":"crossref","first-page":"e759","DOI":"10.1038\/tp.2016.25","article-title":"Is increased antidepressant exposure a contributory factor to the obesity pandemic?","volume":"6","author":"Lee","year":"2016","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0110","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1097\/FBP.0b013e328357bd62","article-title":"Baclofen reduces binge eating in a double-blind, placebo-controlled, crossover study","volume":"23","author":"Corwin","year":"2012","journal-title":"Behav. Pharmacol."},{"key":"10.1016\/j.cct.2017.10.007_bb0115","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4088\/JCP.v68n0306","article-title":"Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial","volume":"68","author":"McElroy","year":"2007","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0120","doi-asserted-by":"crossref","first-page":"802","DOI":"10.4088\/JCP.v63n0909","article-title":"Venlafaxine treatment of binge-eating disorder associated with obesity: a series of 35 patients","volume":"63","author":"Malhotra","year":"2002","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0125","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/ijo.2013.145","article-title":"Effect of combined naltrexone and bupropion therapy on the brain's reactivity to food cues","volume":"38","author":"Wang","year":"2014","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.cct.2017.10.007_bb0130","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1177\/070674370204700309","article-title":"Topiramate use in obese patients with binge eating disorder: an open study","volume":"47","author":"Appolinario","year":"2002","journal-title":"Can. J. Psychiatr."},{"key":"10.1016\/j.cct.2017.10.007_bb0135","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1176\/appi.ajp.160.2.255","article-title":"Topiramate in the treatment of binge eating disorder associated with obesity: a randomized, placebo-controlled trial","volume":"160","author":"McElroy","year":"2003","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0140","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1001\/jamapsychiatry.2014.2162","article-title":"Efficacy and safety of lisdexamfetamine for treatment of adults with moderate to severe binge-eating disorder: a randomized clinical trial","volume":"72","author":"McElroy","year":"2015","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0145","series-title":"Guideline Watch (August 2012): Practice Guideline for the Treatment of Patients with Eating Disorders","first-page":"416","volume":"12","author":"Yager","year":"2014"},{"key":"10.1016\/j.cct.2017.10.007_bb0150","series-title":"Eating disorders: Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders","first-page":"1","author":"National Institute for Clinical Excellence","year":"2004"},{"key":"10.1016\/j.cct.2017.10.007_bb0155","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1176\/appi.ajp.159.1.96","article-title":"A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment","volume":"159","author":"Romano","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0160","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/00004714-199602000-00003","article-title":"Fluvoxamine in prevention of relapse in bulimia nervosa: effects on eating-specific psychopathology","volume":"16","author":"Fichter","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.10.007_bb0165","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00004850-199510030-00005","article-title":"Naltrexone use in the treatment of anorexia nervosa and bulimia nervosa","volume":"10","author":"Marrazzi","year":"1995","journal-title":"Int. Clin. Psychopharmacol."},{"key":"10.1016\/j.cct.2017.10.007_bb0170","article-title":"Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial","author":"Faris","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.cct.2017.10.007_bb0175","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.genhosppsych.2008.02.002","article-title":"Efficacy of topiramate in bulimia nervosa and binge-eating disorder: a systematic review","volume":"30","author":"Arbaizar","year":"2008","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0180","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/ijo.2013.74","article-title":"Addiction potential of phentermine prescribed during long-term treatment of obesity","volume":"38","author":"Hendricks","year":"2014","journal-title":"Int. J. Obes."},{"key":"10.1016\/j.cct.2017.10.007_bb0185","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1586\/ecp.13.13","article-title":"Fixed-dose combination of phentermine-topiramate for the treatment of obesity","volume":"6","author":"Halpern","year":"2013","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.cct.2017.10.007_bb0190","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/1098-108X(200011)28:3<325::AID-EAT10>3.0.CO;2-3","article-title":"Open treatment of overweight binge eaters with phentermine and fluoxetine as an adjunct to cognitive-behavioral therapy","volume":"28","author":"Devlin","year":"2000","journal-title":"Int. J. Eat. Disord."},{"key":"10.1016\/j.cct.2017.10.007_bb0195","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1210\/en.2012-1272","article-title":"Topiramate treatment improves hypothalamic insulin and leptin signaling and action and reduces obesity in mice","volume":"153","author":"Caricilli","year":"2012","journal-title":"Endocrinology"},{"key":"10.1016\/j.cct.2017.10.007_bb0200","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1002\/oby.20584","article-title":"Evaluation of phentermine and topiramate versus phentermine\/topiramate extended-release in obese adults","volume":"21","author":"Aronne","year":"2013","journal-title":"Obesity (Silver Spring)"},{"key":"10.1016\/j.cct.2017.10.007_bb0205","doi-asserted-by":"crossref","first-page":"2424","DOI":"10.1001\/jama.2016.7602","article-title":"Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis","volume":"315","author":"Khera","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cct.2017.10.007_bb0210","article-title":"Successful treatment of binge eating disorder with combination phentermine\/topiramate extended release","volume":"17","author":"Guerdjikova","year":"2015","journal-title":"The Prim. Care Companion CNS Dis."},{"key":"10.1016\/j.cct.2017.10.007_bb0215","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/eat.20202","article-title":"Topiramate treatment in bulimia nervosa patients: a randomized, double-blind, placebo-controlled trial","volume":"38","author":"Nickel","year":"2005","journal-title":"Int. J. Eat. Disord."},{"key":"10.1016\/j.cct.2017.10.007_bb0220","series-title":"VI-0521 (QNEXA\u00ae) Advisory Committee Briefing Document","first-page":"1","year":"2012"},{"key":"10.1016\/j.cct.2017.10.007_bb0225","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1192\/bjp.154.6.807","article-title":"The validity of the eating disorder examination and its subscales","volume":"154","author":"Cooper","year":"1998","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0230","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.eatbeh.2012.09.002","article-title":"Norms and discriminative validity of the Eating Disorder Examination Questionnaire (EDE-Q)","volume":"13","author":"Aardoom","year":"2012","journal-title":"Eat. Behav."},{"issue":"11","key":"10.1016\/j.cct.2017.10.007_bb0235","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","article-title":"The Yale-Brown Obsessive Compulsive Scale. I. Development, use, and reliability","volume":"46","author":"Goodman","year":"1989","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.cct.2017.10.007_bb0240","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/0022-3999(85)90010-8","article-title":"The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger","volume":"29","author":"Stunkard","year":"1985","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.cct.2017.10.007_bb0245","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.appet.2008.12.003","article-title":"Preliminary validation of the Yale Food Addiction Scale","volume":"52","author":"Gearhardt","year":"2009","journal-title":"Appetite"},{"key":"10.1016\/j.cct.2017.10.007_bb0250","doi-asserted-by":"crossref","DOI":"10.1111\/j.1751-9861.1999.tb00051.x","article-title":"Binge Eating Scale: further assessment of validity and reliability","author":"Timmerman","year":"1999","journal-title":"J. Appl. Biobehav. Res."},{"key":"10.1016\/j.cct.2017.10.007_bb0255","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J. Gen. Intern. Med."}],"container-title":["Contemporary Clinical Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714417303452?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551714417303452?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T08:49:35Z","timestamp":1761554975000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551714417303452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":51,"alternative-id":["S1551714417303452"],"URL":"https:\/\/doi.org\/10.1016\/j.cct.2017.10.007","relation":{},"ISSN":["1551-7144"],"issn-type":[{"value":"1551-7144","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Study protocol and rationale for a randomized double-blinded crossover trial of phentermine-topiramate ER versus placebo to treat binge eating disorder and bulimia nervosa","name":"articletitle","label":"Article Title"},{"value":"Contemporary Clinical Trials","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cct.2017.10.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}